RIVASTIGMINE ( DrugBank: Rivastigmine )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
5進行性核上性麻痺2
6パーキンソン病13
13多発性硬化症/視神経脊髄炎2

5. 進行性核上性麻痺


臨床試験数 : 89 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00522015
(ClinicalTrials.gov)
February 200827/8/2007Efficacy Study for Treatment of Dementia in Progressive Supranuclear PalsyRivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 StudyProgressive Supranuclear Palsy;DementiaDrug: rivastigmineUniversity Hospital TuebingenNULLRecruiting50 YearsN/ABoth20Phase 2Germany
2EUCTR2006-006166-42-DE
(EUCTR)
17/07/200702/01/2007Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie -Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie - Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and donepezil did not point out a definite benefit. In contrast, first clinical observations concerning an effect with rivastigmine in PSP with dementia were promising. This may be due to the fact, that rivastigmine excerts a double action inhibiting both the acetylcholin- and the buturylcholinesterase.Trade Name: Exelon 1,5 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
Trade Name: Exelon 3,0 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
Trade Name: Exelon 6,0 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
University of TuebingenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Germany

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04226248
(ClinicalTrials.gov)
January 2, 20205/12/2019CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.Parkinson DiseaseDrug: Rivastigmine Transdermal System;Other: Placebo Transdermal SystemUniversity of BristolRoyal United Hospitals Bath NHS Foundation TrustRecruiting18 YearsN/AAll600Phase 3United Kingdom
2EUCTR2018-003219-23-GB
(EUCTR)
28/06/201904/06/2019CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease)CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease - CHIEF-PD This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease
MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h
Product Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h
Product Code: N/A
INN or Proposed INN: Rivastigmine
Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)
Trade Name: Rivastigmine Luye Transdermal Patch- 9.5mg/24h
Product Name: Rivastigmine Luye Transdermal Patch- 9.5mg/24h
INN or Proposed INN: Rivastigmine
Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)
Product Name: Rivastigmine transdermal system 13.3 mg/24 h
Product Code: RIV-TDS 13.3 mg/24 h
INN or Proposed INN: Rivastigmine
Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)
University of BristolNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3United Kingdom
3NCT03840837
(ClinicalTrials.gov)
May 2, 201911/2/2019Cholinergic Neurotransmission in Mobility and Cognition in Parkinson DiseaseCholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson DiseaseParkinson Disease;Parkinson Disease DementiaDrug: Rivastigmine transdermal patchUniversity of Maryland, BaltimoreNational Institute on Aging (NIA)Completed18 YearsN/AAll31Phase 4United States
4NCT01856738
(ClinicalTrials.gov)
November 201314/5/2013Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s DiseaseCholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial.Parkinson's DiseaseDrug: Rivastigmine;Drug: Placebo (for rivastigmine)VU University Medical CenterAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);Atrium Medical Center;University Medical Center Groningen;Leiden University Medical Center;University Medical Center Nijmegen;International Parkinson Fonds Germany GmbH;ZonMw: The Netherlands Organisation for Health Research and DevelopmentTerminated40 YearsN/AAll91Phase 4Netherlands
5EUCTR2013-001722-25-NL
(EUCTR)
27/08/201312/08/2013Rivastigmine as an early treatment for visual hallucinations in Parkinson’s disease (CHEVAL)Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL) - CHEVAL Parkinson's disease
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Rivastigmine CFVU University Medical CenterNULLNot Recruiting Female: yes
Male: yes
168 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesNetherlands
6EUCTR2011-003053-25-GB
(EUCTR)
18/06/201201/05/2012The ReSPonD Study -Rivastigmine to Stabilise gait in Parkinson’s Disease. A study looking at whether Rivastigmine, a drug that can augment mental function, can stabilise walking in people with Parkinson's disease who have fallen.A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson’s disease who have fallen. - ReSPonD Study - Rivastigmine to Stabilise gait in Parkinson’s Disease Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Exelon ®
Product Name: ENA713
Product Code: N/A
INN or Proposed INN: Rivastigmine
Trade Name: Exelon
Product Name: ENA713
Product Code: N/A
INN or Proposed INN: Rivastigmine
Trade Name: Exelon
Product Name: ENA713
Product Code: N/A
INN or Proposed INN: Rivastigmine
Trade Name: Exelon
Product Name: ENA713
Product Code: N/A
INN or Proposed INN: Rivastigmine
Research and Enterprise DepartmentNULLNot Recruiting Female: yes
Male: yes
130 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
7NCT01519271
(ClinicalTrials.gov)
December 201110/1/2012Mild Cognitive Impairment in Parkinson's DiseaseA Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's DiseaseParkinson's Disease;Mild Cognitive ImpairmentDrug: Exelon Patch (rivastigmine transdermal system);Drug: Placebo PatchesUniversity of PennsylvaniaNULLCompleted40 Years85 YearsAll28Phase 4United States
8NCT00988117
(ClinicalTrials.gov)
April 201029/9/2009The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking ProblemsThe Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD)Parkinsons Disease With Dementia;Parkinsons Disease With Mild to Moderate Memory and/or Thinking ProblemsDrug: Rivastigmine Patch 9.5 cm2University of California, San FranciscoNovartisCompleted55 YearsN/AAll15Phase 4United States
9NCT00767091
(ClinicalTrials.gov)
March 20091/9/2008Study of Rivastigmine to Treat Parkinsonian Apathy Without DementiaA Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentric TrialParkinson's Disease;Apathy;no DementiaDrug: rivastigmine;Drug: placeboUniversity Hospital, LilleNULLCompleted15 Years80 YearsBoth40Phase 3France
10EUCTR2007-000350-31-IT
(EUCTR)
02/10/200811/02/2008A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson?s disease (PDD) - NDA 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson?s disease (PDD) - ND mild to moderately severe dementia associated with Parkinson?s disease (PDD)
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease
Product Name: Exelon path transdermal
Product Code: ENA713B
INN or Proposed INN: Rivastigmine
Trade Name: EXELON
INN or Proposed INN: Rivastigmine
Trade Name: EXELON
INN or Proposed INN: Rivastigmine
Trade Name: EXELON
INN or Proposed INN: Rivastigmine
Trade Name: EXELON
INN or Proposed INN: Rivastigmine
Product Name: Exelon path transdermal
Product Code: ENA713B
INN or Proposed INN: Rivastigmine
NOVARTIS FARMANULLNot RecruitingFemale: yes
Male: yes
550France;Spain;Italy
11EUCTR2007-000350-31-ES
(EUCTR)
13/02/200821/12/2007Estudio prospectivo, multicéntrico y en condiciones abiertas de 76 semanas de duración para evaluar el efecto a largo plazo de Exelon® cápsula y parche transdérmico en el empeoramiento de los síntomas motores subyacentes de la EP en pacientes con demencia leve a moderadamente grave asociada a enfermedad de Parkinson (DEP)Estudio prospectivo, multicéntrico y en condiciones abiertas de 76 semanas de duración para evaluar el efecto a largo plazo de Exelon® cápsula y parche transdérmico en el empeoramiento de los síntomas motores subyacentes de la EP en pacientes con demencia leve a moderadamente grave asociada a enfermedad de Parkinson (DEP) Demencia leve a moderadamente grave asociada a enfermedad de Parkinson (DEP).
MedDRA version: 9.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon 4.6 mg/24 h transdermal patch
INN or Proposed INN: rivastigmine
Trade Name: Exelon 9.5 mg/24 h transdermal patch
INN or Proposed INN: rivastigmine
Novartis Farmacéutica S.ANULLNot RecruitingFemale: yes
Male: yes
550Phase 3France;Spain;Italy
12EUCTR2007-000350-31-FR
(EUCTR)
22/01/200825/10/2007A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD).A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD). Mild to moderately severe dementia associated with Parkinson’s disease (PDD).
MedDRA version: 9.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon
INN or Proposed INN: rivastigmine
Trade Name: Exelon 4.6 mg/24 h transdermal patch
INN or Proposed INN: rivastigmine
Trade Name: Exelon 9.5 mg/24 h transdermal patch
INN or Proposed INN: rivastigmine
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
550France;Spain;Italy
13NCT00623103
(ClinicalTrials.gov)
January 200814/2/2008Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)Parkinson's Disease DementiaDrug: Rivastigmine capsule;Drug: Rivastigmine transdermal patchNovartisNULLCompleted50 Years85 YearsAll583Phase 3United States;Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00881205
(ClinicalTrials.gov)
April 200914/4/2009Rivastigmine in Multiple Sclerosis Patients With Cognitive ImpairmentA 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment PhaseMultiple Sclerosis;Cognitive ImpairmentDrug: Rivastigmine transdermal patch;Drug: PlaceboNovartis PharmaceuticalsNULLTerminated18 Years65 YearsAll86Phase 4Germany
2EUCTR2008-007015-32-DE
(EUCTR)
03/03/2009A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multiple sclerosis, followed by a 1-year open-label treatment phaseA 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multiple sclerosis, followed by a 1-year open-label treatment phase cognitive impairment in Multiple Sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis
Trade Name: Exelon transdermales Pflaster
Product Name: Exelon
Product Code: ENA713
INN or Proposed INN: Rivastigmin
Trade Name: Exelon transdermales Pflaster
Product Name: Exelon
Product Code: ENA713
INN or Proposed INN: Rivastigmin
Trade Name: Exelon transdermales Pflaster
Product Name: Exelon
Product Code: ENA713
INN or Proposed INN: Rivastigmin
Trade Name: Exelon transdermales Pflaster
Product Name: Exelon
Product Code: ENA713
INN or Proposed INN: Rivastigmin
Novartis Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
Germany